Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters











Publication year range
1.
J Sports Med Phys Fitness ; 55(6): 615-20, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25801165

ABSTRACT

AIM: There is little information known about the dietary intakes of older athletes. The purpose of this study was to assess the dietary intakes of full marathon runners over the age of 50 during the 3 days prior to and during a 26.2 mile marathon. METHODS: Participants completed a 3-day food record prior to the marathon and a food recall post-marathon. Dietary records were entered into a nutrient analysis software program and were analyzed for total energy, macronutrients, and micronutrients. RESULTS: The average energy intake based on the 3-day food records was 2670±225 kcal/day, which was below the estimated energy requirement of 3140±102 kcal/day. The participants consumed 56%, 17% and 27% of energy from carbohydrates, protein and fat, respectively, and these were within the acceptable macronutrient distribution ranges. The participants had a favorable omega-6 to omega-3 ratio of 5:1. The participants were consuming 3920±350 mg/day of sodium which is 70% above the goal of 2300 mg/day. The participants met the dietary reference intakes for only half of the micronutrients. Based on the food recall, 87% of the participants' energy intake was from carbohydrates (213±19 g or 852±75 kcal) before and during the marathon. CONCLUSION: Marathon runners over the age of 50 have a balanced diet during the 3 days prior to running a 26.2 mile marathon. Carbohydrates were the main source of energy consumed before and during the marathon.


Subject(s)
Diet , Energy Intake , Running , Diet Records , Dietary Carbohydrates/administration & dosage , Female , Humans , Male , Micronutrients/administration & dosage , Middle Aged , Retrospective Studies
2.
Clin Nutr ESPEN ; 10(5): e155-e159, 2015 Oct.
Article in English | MEDLINE | ID: mdl-28531469

ABSTRACT

BACKGROUND AND AIMS: Elevated levels of circulating omega-3 polyunsaturated fatty acids like alpha linolenic acid (ALA) may be beneficial for cardiovascular health. Circulating ALA concentrations are elevated dramatically by a cholesterol supplemented diet which increases ALA bioavailability through enhanced micelle formation in the intestines. Conversely, it is possible that drugs which inhibit cholesterol metabolism in the intestine may also inhibit fatty acid absorption. The purpose of this study is to determine if a cholesterol absorption inhibitor, ezetimibe, will decrease circulating levels of ALA. METHODS AND RESULTS: Cardiac patients (n = 34) between 44 and 80 years old, requiring statin therapy to regulate blood cholesterol levels, were randomly assigned to one of four groups for a 6 week trial: 1) placebo; 2) ezetimibe therapy; 3) a supplement of flaxseed oil (containing 1.0 g ALA in 2.0 g of flaxseed oil); or 4) ezetimibe and flaxseed oil supplementation. Ingestion of flaxseed oil resulted in a significant increase in circulating ALA levels (6 ug/dl) in patients who were not given ezetimibe. However, in the presence of ezetimibe, circulating ALA levels did not increase significantly even in the presence of flax oil supplementation (a decrease of 4 ug/dl). There were no significant differences amongst the groups in terms of circulating total cholesterol, LDL, HDL, triglyceride levels in the blood. CONCLUSION: Ezetimibe therapy inhibited the absorption of omega-3 fatty acids. Patients receiving ezetimibe therapy may not receive the expected cardiovascular benefits from dietary supplementation with omega-3 fatty acids. CLINICAL TRIAL REGISTRATION: NCT00955227.

6.
Int J Sports Med ; 30(2): 75-9, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19177312

ABSTRACT

An elevation of cardiac injury markers including creatinine kinase (CK), myoglobin (Myo) and cardiac troponin T (cTnT) has been observed in elite athletes following strenuous exercise. The mechanism and significance of this observation however have not been fully elucidated. The goals of this study were: 1) to determine whether these changes in biomarkers also occur in a large, heterogeneous group of non-elite athletes; and 2) to identify possible clinical or biochemical associations. We recruited 129 non-elite runners in 2006, 61 individuals who were taking part in the half (13.1 miles) marathon and 68 individuals participating in the full (26.2 miles) marathon. Demographic data and blood samples were collected for analysis of CK, Myo, cTnT, and Creatinine (Cr) levels within two hours of race start, at race completion, and 1-h post-race for both patient cohorts. In the 61 individuals (40 males, 40+/-12 yrs) completing the half marathon in a mean time of 150+/-20 min, 90.3%, 65.2%, and 30.6% of the subjects exhibited significant elevations in Myo, CK, and cTnT, respectively immediately post race and 100%, 74.9% and 45.9% in the same biomarkers one hour-post race. In the 68 individuals (44 males, 42+/-14 yrs) completing the full marathon in a mean time of 310+/-30 min, 95.3%, 70.2% and 35.7% exhibited significant elevations in Myo, CK and cTnT respectively immediately post race and 100%, 78.5% and 52.8% in the same biomarkers one hour-post race. The elevation in cTnT levels post-race were modestly associated with the time required to complete the race for the entire cohort of marathon runners. The serum levels of Cr, CK, and Myo post-race did not correlate however with age, sex, BMI, level of training, or prior marathon experience. Elevations of cardiac injury markers in non-elite athletes are extremely common following the completion of endurance events and correlate to the increased endurance time. Whether the increase in the levels of these enzymes represents true myocardial injury or a result of the release of cTnT from the myocytes requires further investigation.


Subject(s)
Cardiovascular System/physiopathology , Creatine Kinase/blood , Creatinine/blood , Exercise Tolerance/physiology , Myoglobin/blood , Running/physiology , Troponin T/blood , Adaptation, Physiological , Adult , Female , Humans , Incidence , Male , Risk Factors
7.
Chest ; 120(3): 1023-4, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11555543

ABSTRACT

A 26-year-old woman presented with fever, chills, and back pain 6 weeks postpartum. An infused CT scan of the abdomen and pelvis with IV contrast confirmed septic pelvic vein thrombophlebitis as the diagnosis. To the best of our knowledge, this is the first case report describing such a massive thrombophlebitis extending from the superior vena cava to the femoral vein inferiorly responsive to conventional anticoagulation therapy. This exceptional case reminds us to entertain septic pelvic thrombophlebitis in the differential of any patient who presents with fever and back pain of unknown etiology.


Subject(s)
Back Pain/etiology , Fever/etiology , Puerperal Disorders/diagnosis , Thrombophlebitis/diagnosis , Adult , Female , Femoral Vein , Humans , Iliac Vein , Ovary/blood supply , Thrombophlebitis/complications , Tomography, X-Ray Computed/methods , Vena Cava, Inferior , Vena Cava, Superior
9.
Ann Plast Surg ; 46(2): 174-7, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11216616

ABSTRACT

Although a rare diagnosis, with few reports in the literature, calcific myonecrosis is a diagnosis that must be entertained in individuals presenting with expanding masses in the muscle compartments occurring years after an initial injury. The authors report a previously healthy 66-year-old man with an expanding right lower extremity mass felt initially to be an abscess. Despite presumably appropriate antimicrobial therapy, the lesion continued to expand, causing pain and loss of function. The patient subsequently underwent extensive debridement and free muscle flap transfer with an excellent outcome. This patient serves to remind us that, although calcific myonecrosis is an uncommonly encountered condition, it must be maintained in the differential diagnosis of an expanding muscle compartment mass.


Subject(s)
Muscular Diseases/etiology , Muscular Diseases/surgery , Aged , Calcinosis , Compartment Syndromes/complications , Debridement , Humans , Male , Muscular Diseases/pathology , Necrosis , Surgical Flaps
11.
Am J Physiol Heart Circ Physiol ; 279(6): H3020-30, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11087260

ABSTRACT

Angiotensin II (angiotensin) and transforming growth factor (TGF)-beta(1) play an important role in cardiac fibrosis. We examined Smad proteins in 8-wk post-myocardial infarction (MI) rat hearts. AT(1) blockade (losartan) attenuated the activation of TGF-beta(1) in target tissues. Losartan administration (8 wk, 15 mg. kg(-1). day(-1)) normalized total Smad 2 overexpression in infarct scar and remnant heart tissue and normalized Smad 4 in infarct scar. Phosphorylated Smad 2 (P-Smad 2) staining decreased in cytosol from failing heart vs. the control, which was normalized by losartan, suggesting augmented P-Smad 2 movement into nuclei in untreated failing hearts. Using adult primary rat fibroblasts treated with angiotensin (10(-6) M), we noted rapid translocation (15 min) of P-Smad 2 into the nuclei from the cytosol. Nuclear P-Smad 2 protein level increased with angiotensin treatment, which was blocked by losartan. We conclude that angiotensin may influence total Smad 2 and 4 expression in post-MI heart failure and that angiotensin treatment is associated with rapid P-Smad 2 nuclear translocation in isolated fibroblasts. This study suggests that cross talk between angiotensin and Smad signaling is associated with fibrotic events in post-MI hearts.


Subject(s)
Angiotensin II/metabolism , DNA-Binding Proteins/metabolism , Myocardial Infarction/metabolism , Trans-Activators/metabolism , Active Transport, Cell Nucleus/physiology , Angiotensin Receptor Antagonists , Animals , Antihypertensive Agents/pharmacology , Cardiomegaly/metabolism , Cardiomegaly/pathology , Cell Nucleus/chemistry , Cell Nucleus/metabolism , Cells, Cultured , Collagen/analysis , Cytosol/chemistry , Cytosol/metabolism , DNA-Binding Proteins/analysis , Fibroblasts/chemistry , Fibroblasts/cytology , Fibroblasts/metabolism , Heart Failure/metabolism , Heart Failure/pathology , In Vitro Techniques , Losartan/pharmacology , Male , Myocardial Infarction/pathology , Myocardium/chemistry , Myocardium/pathology , Phosphorylation , Rats , Rats, Sprague-Dawley , Receptor Cross-Talk/physiology , Receptor, Angiotensin, Type 1 , Receptor, Angiotensin, Type 2 , Receptors, Angiotensin/metabolism , Smad2 Protein , Smad4 Protein , Trans-Activators/analysis , Transforming Growth Factor beta/analysis , Transforming Growth Factor beta/biosynthesis , Vimentin/analysis
14.
Cardiovasc Res ; 35(2): 223-32, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9349385

ABSTRACT

OBJECTIVE: Previous work has shown that cardiac fibrosis occurs after myocardial infarction (MI) in non-infarcted ventricular tissue and that this event is associated with abnormal cardiac function. Our aim was to investigate the effect of AT1 receptor blockade on cardiac collagen remodeling in post-MI rat heart remote from the infarct site by addressing collagen mRNA abundance, posttranslational hydroxylation of collagen monomers, and mature collagen deposition. Prolyl 4-hydroxylase (PH) mediates hydroxylation of procollagen alpha-chains in the endoplasmic reticulum of cardiac fibroblasts and thus regulates the downstream formation and secretion of helical procollagen molecules. METHODS: The effects of losartan (15 mg/kg/day) on collagen deposition and mRNA abundance were monitored in viable left and right ventricles in sham-operated (control) and experimental groups in the presence or absence of losartan. Immunoreactive PH concentration in viable tissues as well as cardiac function in control and experimental groups was determined by ELISA. RESULTS: Immunohistochemical staining and 4-hydroxyproline assays confirmed that losartan treatment attenuates fibrosis in experimental hearts. Northern analysis revealed that losartan treatment of 1, 2, or 4 week experimental groups had no effect on collagen mRNA abundance compared to untreated post-MI rats. On the other hand, immunoreactive PH concentration was significantly decreased in the post-MI group treated with losartan. Determination of cardiac mass and cardiac function revealed that losartan treatment was associated with attenuated cardiac hypertrophy and improved left ventricular (LV) function in experimental animals. CONCLUSIONS: AT1 blockade is associated with a significant decrease in cardiac fibrosis in treated post-MI rats, and this trend is positively correlated to a significant decrease in immunoreactive PH compared to untreated experimental animals. The expression of cardiac PH may be regulated by angiotensin via AT1 receptor activation, and the suppression of PH with losartan treatment may be an important mechanism for modulation of collagen deposition in the post-MI rat heart.


Subject(s)
Angiotensin II , Angiotensin Receptor Antagonists , Antihypertensive Agents/therapeutic use , Losartan/therapeutic use , Myocardial Infarction/drug therapy , Animals , Biomarkers/analysis , Blotting, Northern , Collagen/genetics , Collagen/metabolism , Hydrogen-Ion Concentration , Hydroxyproline/analysis , Immunohistochemistry , Male , Myocardial Infarction/metabolism , Myocardial Infarction/pathology , Myocardium/metabolism , Myocardium/pathology , RNA, Messenger/analysis , Rats , Rats, Sprague-Dawley , Ventricular Function, Left/drug effects
15.
Mol Cell Biochem ; 165(1): 31-45, 1996 Dec 06.
Article in English | MEDLINE | ID: mdl-8974079

ABSTRACT

Although increased deposition of collagen proteins has been described after myocardial infarction (MI), little is known of time-dependent transcriptional alteration of specific cardiac collagen sub-types as well as the degradative mechanisms for cardiac collagens in right and left ventricular myocardium remote to large left ventricular infarction. We sought to study collagen mRNA abundance and the deposition of specific collagen subtypes in noninfarcted left and right rat heart muscle at different times after MI. We also assessed the activity of different myocardial matrix metalloproteinases (MMP) using zymography to gain some information about degradative pathways for collagen. Furthermore, we assessed passive compliance properties of the right ventricle in experimental hearts. Finally we investigated the role of the renin angiotensin system in the collagen gene expression by administration of an angiotensin converting enzyme (ACE) inhibitor (ramipril) and an angiotensin II receptor type I antagonist (losartan) in experimental animals. We observed that the mRNA abundance of types I and III collagen were increased 3 days after myocardial infarction in both viable left and uninfarcted right ventricular tissues, that they peaked at 7-14 days, and were maintained at relatively high levels in the 28 and 56 days experimental groups. Stiffness of the right ventricular myocardium was significantly increased in the 56 days experimental group when compared to that of control values. These findings correlated with increased immunohistochemical staining patterns of different collagen species in the surviving right (and left) cardiac interstitium of 14, 28, and 56 day experimental cardiac groups. The elevation of fibrillar collagen mRNA abundance in noninfarcted muscle from ventricular chambers was not significantly altered after treatment of experimental animals with ramipril and losartan for up to 14 days. MMP activity was increased in viable left ventricle at 14, 28 and 56 days and at 14 days in the right ventricle in experimental animals when compared to controls. These results indicated that (1) activation of transcription of collagen types I and III gene occurs in acute and chronic MI, and that fibrillar collagen proteins are deposited in the noninfarcted cardiac interstitium after a lag period relative to increased corresponding mRNA abundance; (2) an increase in MMP activity in chronic experimental hearts indicates that increased collagen deposition may be due to an increment in collagen synthesis rather by reduced degradation of collagen, and that MMP activation may be important in remodeling of the noninfarcted cardiac stroma; (3) an increase of right ventricular stiffness was associated with increased deposition of collagen; (4) as losartan treatment is not associated with any normalization of elevated collagen mRNA abundance, the upregulation of collagen gene expression in this model is not mediated by AT1 receptor; and (5) the reduction of cardiac fibrosis mediated by ACE inhibition and losartan treatment may reside at the post-translational level in cardiac collagen metabolism.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/pharmacology , Anti-Arrhythmia Agents/pharmacology , Biphenyl Compounds/pharmacology , Collagen/genetics , Collagen/metabolism , Gene Expression Regulation/drug effects , Imidazoles/pharmacology , Myocardial Infarction/genetics , Myocardial Infarction/metabolism , Myocardium/metabolism , Ramipril/pharmacology , Tetrazoles/pharmacology , Animals , Blotting, Northern , Collagen/immunology , Collagenases/metabolism , Extracellular Matrix/metabolism , Immunohistochemistry , Losartan , Male , Metalloendopeptidases/metabolism , Myocardial Infarction/pathology , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Transcription, Genetic , Ventricular Function, Right , Wound Healing/genetics
16.
Am J Anat ; 186(3): 285-99, 1989 Nov.
Article in English | MEDLINE | ID: mdl-2694840

ABSTRACT

Recent studies have indicated that pulmonary intravascular macrophages (PIMs) are a resident cell population which in structure and function resemble mature macrophages of the mononuclear phagocyte system (MPS) in various domestic species, particularly the ruminants. The ultrastructural features of PIMs of the goat and calf lungs were studied by using vascular perfusion and direct airway instillation of fixatives. Staining with tannic acid as a component of paraformaldehyde-glutaraldehyde-based fixative revealed the presence of an electron-dense coat on the surface of the cell membrane of the PIMs. The surface coat disappeared after heparin infusion and after enzymatic digestion with lipolytic lipase, suggesting that the surface coat was predominantly lipoprotein in nature. The lipoprotein coat was organized in the form of a linear chain of spherical globules with a consistent periodicity created by the intervening translucent space between individual globules. The surface coat was separated from the outer-leaflet of the cell membrane by an empty space measuring 35-39 nm in width. PIMs possessed a significant number of coated pits and coated vesicles, the cell organelles of receptor-mediated endocytosis of lipoproteins. In concurrence with the coated pits and vesicles, microtubules, multivesicular bodies, and lipoprotein-positive vesicles were also observed. It is conceivable that PIMs are involved in lipid metabolism and are the major source of vasoactive substances, which significantly influence both the dynamics of pulmonary circulation and the surfactant turnover of the ruminant lung.


Subject(s)
Goats/blood , Lung/blood supply , Macrophages/cytology , Animals , Cattle , Cell Membrane/drug effects , Cell Membrane/physiology , Cell Membrane/ultrastructure , Cholesterol, LDL/blood , Fatty Acids , Female , Heparin/administration & dosage , Heparin/pharmacology , Histological Techniques , Injections, Intravenous , Lipase/blood , Lung/cytology , Macrophages/physiology , Macrophages/ultrastructure , Male , Microscopy, Electron , Microtubules/ultrastructure , Organelles/ultrastructure , Triglycerides/blood
SELECTION OF CITATIONS
SEARCH DETAIL